US drug regulator blocks Regeneron’s blood cancer therapy
The US regulatory body has rejected Regeneron Pharmaceuticals, Inc.,’s blood cancer drug as it did not meet the pre-approval standards of the agency.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
The US regulatory body has rejected Regeneron Pharmaceuticals, Inc.,’s blood cancer drug as it did not meet the pre-approval standards of the agency.
The US Food and Drug Administration has approved the Darzalex Faspro combination drug therapy of Janssen Research and Development for treating blood cancer.
HQ Team February 21, 2024: Johnson & Johnson announced that USFDA had approved a bi-weekly dose of its blood cancer therapy Tecvayli. The regulatory.
The European Medicines Agency has recommended the stoppage of conditional marketing authorisation for GSK’s Blenrep (belantamab mafodotin), a medicine used to treat cancer of.
HQ Team August 15, 2023: The USFDA has granted accelerated approval for Pfizer Inc’s Elrexfio to treat incurable blood cancer, multiple myeloma, that.
HQ Team August 11, 2023: The USFDA has granted accelerated approval to Janssen Pharmaceutical Companies for its cancer antibody treatment, Talvey, to treat.
A US court dismissed all claims against Dr. Reddy's Laboratories Inc., a wholly-owned subsidiary, in an antitrust complaint related to the cancer drug.
J &J gets approval from FDA for medicine to treat a type of blood cancer-Multiple Myeloma